Compare Twist Bioscience Corp (TWST) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wayfair Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Wayfair Inc trades at $100.12 (market cap $13.69B). The key difference: Wayfair Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| TWST | W | |
|---|---|---|
Market Cap | $8.42B | $13.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $153.10 | $119.05 |
52-Week Low | $24.16 | $57.40 |
Enterprise Value | $8.35B | $16.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Wayfair (W) trades at $99.96, up 0.53% today, with a bullish technical signal supported by moving averages. The stock shows strong revenue growth of 7.5% year-over-year in Q2 2026 and has beaten earnings estimates in two of the last three quarters. Recent positive sentiment follows the company's 10th store announcement and a golden cross technical pattern. However, the company continues to report net losses with a -2.49% net income margin and carries significant debt with a 95.11% debt-to-asset ratio.
Wayfair presents a mixed investment case with strong revenue momentum and market share gains offset by persistent profitability challenges. The consensus price target of $125.14 suggests 25% upside potential, supported by 53.57% analyst buy ratings. Key risks include ongoing net losses, high leverage, and consumer spending sensitivity. The stock's technical strength and expansion initiatives provide catalysts, but profitability improvement remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
